MXPA03007422A - Quinolinona triciclica y quinolina triciclica como compuestos moduladores del receptor de androgeno. - Google Patents

Quinolinona triciclica y quinolina triciclica como compuestos moduladores del receptor de androgeno.

Info

Publication number: MXPA03007422A
Authority: MX; Mexico
Prior art keywords: tricyclic; quinolinone; androgen receptor; receptor modulator; quinoline
Prior art date: 2001-02-23

Application number

MXPA03007422A

Other languages

English (en)

Inventor

Donald S Karanewsky

Original Assignee

Ligand Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-23

Filing date

2002-02-23

Publication date

2003-12-04

2002-02-23 Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc

2003-12-04 Publication of MXPA03007422A publication Critical patent/MXPA03007422A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

MXPA03007422A 2001-02-23 2002-02-23 Quinolinona triciclica y quinolina triciclica como compuestos moduladores del receptor de androgeno. MXPA03007422A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27111501P	2001-02-23	2001-02-23
PCT/IB2002/000538 WO2002068427A1 (en)	2001-02-23	2002-02-23	Tricyclic quinolinone and tricyclic quinoline as androgen receptor modulator compounds

Publications (1)

Publication Number	Publication Date
MXPA03007422A true MXPA03007422A (es)	2003-12-04

Family

ID=23034258

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA03007422A MXPA03007422A (es)	2001-02-23	2002-02-23	Quinolinona triciclica y quinolina triciclica como compuestos moduladores del receptor de androgeno.

Country Status (8)

Country	Link
US (2)	US7214690B2 (es)
EP (1)	EP1368357A1 (es)
JP (1)	JP2004524317A (es)
CN (1)	CN1492872A (es)
BR (1)	BR0207543A (es)
CA (1)	CA2434727A1 (es)
MX (1)	MXPA03007422A (es)
WO (1)	WO2002068427A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2383077A1 (en) *	1999-08-27	2001-03-08	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
US6566372B1 (en)	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
US20040260108A1 (en) *	2001-06-25	2004-12-23	Dalton James T.	Metabolites of selective androgen receptor modulators and methods of use thereof
US7026484B2 (en) *	2001-02-23	2006-04-11	Ligand Pharmaceuticals Incorporated	Tricyclic androgen receptor modulator compounds and methods
US7214690B2 (en) *	2001-02-23	2007-05-08	Ligand Pharmaceuticals Incorporated	Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
WO2003090672A2 (en) *	2002-04-26	2003-11-06	Ortho-Mcneil Pharmaceutical, Inc.	2-(quinolonyl)-fused heterocycles as androgen receptor modulators
JP2006515605A (ja) *	2003-01-17	2006-06-01	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	アンドロゲンレセプターアンタゴニスト
US20060148893A1 (en) *	2003-06-10	2006-07-06	Blanc Jean-Baptiste E	Chemical compounds
EP1656142A4 (en) *	2003-08-22	2011-06-22	Ligand Pharm Inc	6-CYCLOAMINO-2-QUINOLINONE DERIVATIVES AS MODULATORS ANDROGEN RECEPTOR COMPOUNDS
US8519158B2 (en) *	2004-03-12	2013-08-27	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
UA87854C2 (en) *	2004-06-07	2009-08-25	Мерк Энд Ко., Инк.	N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
RU2007130558A (ru)	2005-01-10	2009-02-20	Акэдиа Фармасьютикалз Инк. (Us)	Производные аминофенола в качестве селективных модуляторов андрогеновых рецепторов
CA2598216C (en) *	2005-06-17	2014-04-08	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
CA2620275A1 (en) *	2005-08-26	2007-03-01	Thomas S. Scanlan	Non-steroidal antiandrogens
WO2007075884A2 (en) *	2005-12-21	2007-07-05	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
BRPI0821090B8 (pt)	2007-12-21	2021-05-25	Ligand Pharm Inc	moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo
DE102008049323A1 (de) *	2008-09-29	2010-04-01	Henkel Ag & Co. Kgaa	Neue Entwicklerkomponenten
EP3613418A1 (en)	2014-01-17	2020-02-26	Ligand Pharmaceuticals, Inc.	Methods and compositions for modulating hormone levels
AR103598A1 (es)	2015-02-02	2017-05-24	Forma Therapeutics Inc	Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac
US10239845B2 (en)	2015-02-02	2019-03-26	Forma Therapeutics, Inc.	3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10555935B2 (en)	2016-06-17	2020-02-11	Forma Therapeutics, Inc.	2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
SG11202008531RA (en) *	2018-03-06	2020-10-29	Beijing Scitech Mq Pharmaceuticals Ltd	Oxazino-quinazoline and Oxazino-quinoline Type Compound, Preparation Method and Uses Thereof
KR20220003554A (ko)	2019-04-19	2022-01-10	리간드 파마슈티칼스 인코포레이티드	화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
CN112442045B (zh) *	2019-09-03	2022-02-18	北京赛特明强医药科技有限公司	一种酰基取代的噁嗪并喹唑啉类化合物、制备方法及其应用
WO2024079276A1 (en) *	2022-10-14	2024-04-18	The University Of Stavanger	Photolytically degradable compounds and methods for synthesising thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3919238A (en)	1973-06-06	1975-11-11	Morton Norwich Products Inc	9-(Substituted amino)imidazo(4,5-f) quinolines
JPS5025595A (es)	1973-07-09	1975-03-18
JPS58170506A (ja) *	1982-03-30	1983-10-07	Sumitomo Chem Co Ltd	変異原性物質の処理法
JPH0615036B2 (ja) *	1984-03-27	1994-03-02	住友化学工業株式会社	フタロシアニンが結合したシリカゲルおよびそれを用いる多環系有機物質の処理法
US5071773A (en) *	1986-10-24	1991-12-10	The Salk Institute For Biological Studies	Hormone receptor-related bioassays
US4777052A (en) *	1987-01-06	1988-10-11	American Health Foundation	Method of treating a foodstuff to inhibit the development of mutagens and related product
US4981784A (en) *	1987-12-02	1991-01-01	The Salk Institute For Biological Studies	Retinoic acid receptor method
EP0434858B1 (fr) *	1989-12-27	1994-02-23	Societe Des Produits Nestle S.A.	Produit de réaction d'un dextranomère greffé et d'un colorant phthalocyanine et son utilisation
JP3047434B2 (ja) *	1990-03-27	2000-05-29	株式会社トクヤマ	フォトクロミック成形体
WO1993022317A1 (en)	1992-05-01	1993-11-11	Kowa Co., Ltd.	Quinoline derivative or salt thereof and remedy for cardiac diseases containing the same
JP2822848B2 (ja) *	1993-06-28	1998-11-11	株式会社ニコン	調光プラスチックレンズ及びその製造方法
US5677336A (en)	1993-10-21	1997-10-14	Ligand Pharmaceuticals Incorporated	Non-steroid androgen receptor antagonist compounds and methods
US6696459B1 (en)	1994-12-22	2004-02-24	Ligand Pharmaceuticals Inc.	Steroid receptor modulator compounds and methods
US5688808A (en)	1994-12-22	1997-11-18	Ligand Pharmaceuticals Incorporated	Steroid receptor modulator compounds and methods
CZ176197A3 (cs)	1994-12-22	1998-09-16	Ligand Pharmaceuticals Incorporated	Modulátory steroidových receptorů a způsoby jejich přípravy a použití
US6017924A (en)	1996-06-27	2000-01-25	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
ES2168650T3 (es)	1996-06-27	2002-06-16	Ligand Pharm Inc	Compuestos y metodos moduladores de receptores de androgenos.
ID18046A (id) *	1996-08-20	1998-02-19	Takeda Chemical Industries Ltd	Senyawa siklik campuran, pembuatan dan penngunaannya.
CA2285402A1 (en) *	1997-04-25	1998-11-05	Kohei Notoya	Amide derivatives, their production and use
US6001846A (en)	1998-02-17	1999-12-14	Ligand Pharmaceuticals Incorporated	Process for the preparation of 1,2-dihydroquinolines
US6093826A (en)	1998-06-08	2000-07-25	Ligand Pharmaceuticals Incorporated	Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines
GB9819019D0 (en)	1998-09-01	1998-10-28	Cerebrus Ltd	Chemical compounds II
CA2383077A1 (en)	1999-08-27	2001-03-08	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
EP1212322A2 (en)	1999-08-27	2002-06-12	Ligand Pharmaceuticals Incorporated	8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
US6566372B1 (en)	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
US6172241B1 (en)	1999-10-15	2001-01-09	Ligand Pharmaceuticals Incorporated	Process for the preparation of 1,2-dihydroquinolines
US7214690B2 (en) *	2001-02-23	2007-05-08	Ligand Pharmaceuticals Incorporated	Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
US7026484B2 (en)	2001-02-23	2006-04-11	Ligand Pharmaceuticals Incorporated	Tricyclic androgen receptor modulator compounds and methods
DE10152217A1 (de) *	2001-10-23	2003-04-30	Patent Treuhand Ges Fuer Elektrische Gluehlampen Mbh	Leuchtstoffzusammensetzung für Niederdruckentladungslampen
EP1656142A4 (en)	2003-08-22	2011-06-22	Ligand Pharm Inc	6-CYCLOAMINO-2-QUINOLINONE DERIVATIVES AS MODULATORS ANDROGEN RECEPTOR COMPOUNDS

2002
- 2002-02-22 US US10/080,503 patent/US7214690B2/en not_active Expired - Lifetime
- 2002-02-23 CN CNA028055292A patent/CN1492872A/zh active Pending
- 2002-02-23 CA CA002434727A patent/CA2434727A1/en not_active Abandoned
- 2002-02-23 WO PCT/IB2002/000538 patent/WO2002068427A1/en active Application Filing
- 2002-02-23 BR BR0207543-1A patent/BR0207543A/pt not_active IP Right Cessation
- 2002-02-23 MX MXPA03007422A patent/MXPA03007422A/es active IP Right Grant
- 2002-02-23 EP EP02702590A patent/EP1368357A1/en not_active Withdrawn
- 2002-02-23 JP JP2002567937A patent/JP2004524317A/ja active Pending
2006
- 2006-11-17 US US11/601,251 patent/US20080300241A9/en not_active Abandoned

Also Published As

Publication number	Publication date
US20020183314A1 (en)	2002-12-05
US7214690B2 (en)	2007-05-08
US20080300241A9 (en)	2008-12-04
WO2002068427A1 (en)	2002-09-06
EP1368357A1 (en)	2003-12-10
JP2004524317A (ja)	2004-08-12
US20070072849A1 (en)	2007-03-29
CA2434727A1 (en)	2002-09-06
BR0207543A (pt)	2004-04-27
CN1492872A (zh)	2004-04-28

Publication	Publication Date	Title
MXPA03007422A (es)	2003-12-04	Quinolinona triciclica y quinolina triciclica como compuestos moduladores del receptor de androgeno.
MXPA03007421A (es)	2003-12-04	Compuestos y metodos moduladores del receptor de androgeno triciclico.
IL159288A0 (en)	2004-06-01	Tetrahydroquinoline derivatives
HUP0700124A2 (en)	2007-06-28	Quinoline compound
AU2002367424A1 (en)	2003-07-24	Androgen receptor antagonists
IL154618A0 (en)	2003-09-17	Quinolinone derivatives
AU2001286243A1 (en)	2002-03-26	Tetrahydroquinoline compounds
GB2376359B (en)	2005-04-20	ESD prevention device enabled latch
GB9904103D0 (en)	1999-04-14	Quinoline derivatives
IL161597A0 (en)	2004-09-27	Therapeutic quinoline compounds with 5-ht-antagonistic properties
AU2003264768A1 (en)	2004-04-23	Tricyclic tetrahydroquinoline antibacterial agents
AU2002347336A1 (en)	2003-06-17	Quinoline derivatives
AU2002215043A1 (en)	2002-05-21	Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
GB0104422D0 (en)	2001-04-11	Quinoline derivative
AU2002347359A1 (en)	2003-06-17	Quinoline derivatives
EP1434786A4 (en)	2009-03-25	ANDROSTAN-17-BETA-CARBOXAMIDE AS MODULATORS OF THE ANDROGEN RECEPTOR
AU2002226356A1 (en)	2002-06-11	Quinoline derivatives as nk-3 antagonists
AU2002236115A1 (en)	2002-09-12	Tricyclic quinolinone and tricyclic quinoline as androgen receptor modulator compounds
AU2002301508A1 (en)	2003-06-12	Security device
AUPR830501A0 (en)	2001-11-08	Rope restraint means
AU2002350913A1 (en)	2003-06-17	Security device
GB0120980D0 (en)	2001-10-24	Security devices
GB0123819D0 (en)	2001-11-21	Security device
AU2002310838A1 (en)	2002-10-28	Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
AU147314S (en)	2002-04-15	Clutch ring

Legal Events

Date	Code	Title	Description
2006-06-27	FG	Grant or registration